Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Novo and rival Eli Lilly, which makes the weight loss drug Zepbound, have filed a flurry of lawsuits against medical spas, wellness clinics, and compounding pharmacies for allegedly selling products ...

The NDA includes a combination of Blenrep with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

The London-based pharmaceutical company said Japan's Ministry of Health, Labour and Welfare has accepted the application to review its Blenrep antibody drug in combination with BorDex or PomDex as a ...

Products including untaxed cigarettes, vapes and banned medicine were found during a shop search. GSK Liquor Stop on Dudley ...

During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest significant market share away from GSK's and Pfizer's products this year.

(Alliance News) - GSK PLC on Friday announced that it has been granted breakthrough therapy designation in China for Blenrep, a treatment for relapsed or refractory multiple myeloma.